Cargando…
A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes
MOTIVATION: Multilevel molecular profiling of tumors and the integrative analysis with clinical outcomes have enabled a deeper characterization of cancer treatment. Mediation analysis has emerged as a promising statistical tool to identify and quantify the intermediate mechanisms by which a gene aff...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879726/ https://www.ncbi.nlm.nih.gov/pubmed/36648331 http://dx.doi.org/10.1093/bioinformatics/btad023 |
_version_ | 1784878754856697856 |
---|---|
author | Huang, Licai Long, James P Irajizad, Ehsan Doecke, James D Do, Kim-Anh Ha, Min Jin |
author_facet | Huang, Licai Long, James P Irajizad, Ehsan Doecke, James D Do, Kim-Anh Ha, Min Jin |
author_sort | Huang, Licai |
collection | PubMed |
description | MOTIVATION: Multilevel molecular profiling of tumors and the integrative analysis with clinical outcomes have enabled a deeper characterization of cancer treatment. Mediation analysis has emerged as a promising statistical tool to identify and quantify the intermediate mechanisms by which a gene affects an outcome. However, existing methods lack a unified approach to handle various types of outcome variables, making them unsuitable for high-throughput molecular profiling data with highly interconnected variables. RESULTS: We develop a general mediation analysis framework for proteogenomic data that include multiple exposures, multivariate mediators on various scales of effects as appropriate for continuous, binary and survival outcomes. Our estimation method avoids imposing constraints on model parameters such as the rare disease assumption, while accommodating multiple exposures and high-dimensional mediators. We compare our approach to other methods in extensive simulation studies at a range of sample sizes, disease prevalence and number of false mediators. Using kidney renal clear cell carcinoma proteogenomic data, we identify genes that are mediated by proteins and the underlying mechanisms on various survival outcomes that capture short- and long-term disease-specific clinical characteristics. AVAILABILITY AND IMPLEMENTATION: Software is made available in an R package (https://github.com/longjp/mediateR). SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. |
format | Online Article Text |
id | pubmed-9879726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98797262023-01-31 A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes Huang, Licai Long, James P Irajizad, Ehsan Doecke, James D Do, Kim-Anh Ha, Min Jin Bioinformatics Original Paper MOTIVATION: Multilevel molecular profiling of tumors and the integrative analysis with clinical outcomes have enabled a deeper characterization of cancer treatment. Mediation analysis has emerged as a promising statistical tool to identify and quantify the intermediate mechanisms by which a gene affects an outcome. However, existing methods lack a unified approach to handle various types of outcome variables, making them unsuitable for high-throughput molecular profiling data with highly interconnected variables. RESULTS: We develop a general mediation analysis framework for proteogenomic data that include multiple exposures, multivariate mediators on various scales of effects as appropriate for continuous, binary and survival outcomes. Our estimation method avoids imposing constraints on model parameters such as the rare disease assumption, while accommodating multiple exposures and high-dimensional mediators. We compare our approach to other methods in extensive simulation studies at a range of sample sizes, disease prevalence and number of false mediators. Using kidney renal clear cell carcinoma proteogenomic data, we identify genes that are mediated by proteins and the underlying mechanisms on various survival outcomes that capture short- and long-term disease-specific clinical characteristics. AVAILABILITY AND IMPLEMENTATION: Software is made available in an R package (https://github.com/longjp/mediateR). SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Oxford University Press 2023-01-17 /pmc/articles/PMC9879726/ /pubmed/36648331 http://dx.doi.org/10.1093/bioinformatics/btad023 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Paper Huang, Licai Long, James P Irajizad, Ehsan Doecke, James D Do, Kim-Anh Ha, Min Jin A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes |
title | A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes |
title_full | A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes |
title_fullStr | A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes |
title_full_unstemmed | A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes |
title_short | A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes |
title_sort | unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879726/ https://www.ncbi.nlm.nih.gov/pubmed/36648331 http://dx.doi.org/10.1093/bioinformatics/btad023 |
work_keys_str_mv | AT huanglicai aunifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT longjamesp aunifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT irajizadehsan aunifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT doeckejamesd aunifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT dokimanh aunifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT haminjin aunifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT huanglicai unifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT longjamesp unifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT irajizadehsan unifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT doeckejamesd unifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT dokimanh unifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes AT haminjin unifiedmediationanalysisframeworkforintegrativecancerproteogenomicswithclinicaloutcomes |